<DOC>
	<DOCNO>NCT01413932</DOCNO>
	<brief_summary>This two part study . The objective Part 1 evaluate safety , tolerability , pharmacokinetics HT-2157 healthy normal volunteer Part 2 randomize , double-blind , placebo-controlled , multiple ( 21-day ) ascending-dose evaluation safety , tolerability , pharmacokinetics , pharmacodynamics HT-2157 patient major depressive disorder</brief_summary>
	<brief_title>Pharmacokinetics - Pharmacodynamic Study HT-2157 Healthy Subjects Patients With Major Depressive Disorder</brief_title>
	<detailed_description>This two part study . The objective Part 1 evaluate safety , tolerability , pharmacokinetics HT-2157 administer 7-days healthy normal volunteer Part 2 randomize , double-blind , placebo-controlled , multiple ascending-dose evaluation safety , tolerability , pharmacokinetics HT-2157 administer 21-days patient major depressive disorder . The primary objective Part 2 ass CNS penetration HT-2157 cerebrospinal fluid . In addition , potential activity HT-2157 patient population may assess use exploratory biologic pharmacodynamic marker potential efficacy</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Main Inclusion Criteria ( Part 1 ) No clinically relevant abnormality Age 18 55 year , inclusive Body Mass Index ( BMI ) 18.5 32 kg/m2 Main Inclusion Criteria ( Part 2 ) No clinically relevant abnormality Age 18 55 year , inclusive Body Mass Index ( BMI ) 18.5 32 kg/m2 MildtoModerate major depressive disorder Main Exclusion Criteria ( Part 1 ) Any disorder would interfere absorption , distribution , metabolism , excretion drug Main Exclusion Criteria ( Part 2 ) Any disorder would interfere absorption , distribution , metabolism , excretion drug Current primary Axis I disorder MDD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>